WindMIL Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 8

WindMIL Therapeutics General Information

Description

Developer of oncology cell therapies designed to translate novel insights in bone marrow immunology into life-saving systems for cancer patients. The company's therapies utilize re-activated T-cells that normally lie dormant and leverage bone marrow-derived lymphocytes to develop immunotherapies to treat cancer patients, enabling healthcare professionals to harness the unique immunologic properties of the bone marrow to lead the way in cancer cell therapies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1812 Ashland Avenue
  • Suite 100
  • Baltimore, MD 21205
  • United States
+1 (410)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 1812 Ashland Avenue
  • Suite 100
  • Baltimore, MD 21205
  • United States
+1 (410)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

WindMIL Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private 01-Jan-2023 Completed Generating Revenue
4. Later Stage VC 26-Jan-2021 Completed Generating Revenue
3. Early Stage VC (Series B) 18-Jun-2018 Completed Generating Revenue
2. Early Stage VC (Series A) 07-Apr-2016 $11M $11M Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view WindMIL Therapeutics’s complete valuation and funding history, request access »

WindMIL Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view WindMIL Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

WindMIL Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of oncology cell therapies designed to translate novel insights in bone marrow immunology into life-saving sys
Biotechnology
Baltimore, MD
11 As of 2024

Gaithersburg, MD
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

WindMIL Therapeutics Competitors (83)

One of WindMIL Therapeutics’s 83 competitors is NexImmune, a Formerly VC-backed company based in Gaithersburg, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD
Senti Bio Formerly VC-backed South San Francisco, CA
Kite Pharma Formerly VC-backed Santa Monica, CA
Beacon Therapeutics Venture Capital-Backed Alachua, FL
DefiniGEN Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 5 of 83 competitors. Get the full list »

WindMIL Therapeutics Patents

WindMIL Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230100744-A1 Methods for enriching marrow infiltrating lymphocytes ("mils"), compositions containing enriched mils, and methods of using enriched mils Pending 28-Feb-2020
US-20220168350-A1 Lung cancer specific marrow infiltrating lymphocytes and uses thereof Inactive 22-Mar-2019
US-20210154233-A1 Marrow infiltrating lymphocytes (mils) expressing chimeric antigen receptors (car), method of manufacturing same, and method of using in therapy Inactive 30-Nov-2018
EP-3870191-A4 Marrow infiltrating lymphocytes (mils) expressing chimeric antigen receptors (car), method of manufacturing same, and method of using in therapy Pending 30-Nov-2018
EP-3870191-A1 Marrow infiltrating lymphocytes (mils) expressing chimeric antigen receptors (car), method of manufacturing same, and method of using in therapy Pending 30-Nov-2018 C07K14/7051
To view WindMIL Therapeutics’s complete patent history, request access »

WindMIL Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

WindMIL Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Catalio Capital Management Venture Capital Minority
Forward Equity Partners PE/Buyout Majority
FoxKiser Corporation Minority
Kintegral Asset Management Asset Manager Minority
Medivate Partners PE/Buyout Minority
You’re viewing 5 of 8 investors. Get the full list »

WindMIL Therapeutics FAQs

  • When was WindMIL Therapeutics founded?

    WindMIL Therapeutics was founded in 2015.

  • Where is WindMIL Therapeutics headquartered?

    WindMIL Therapeutics is headquartered in Baltimore, MD.

  • What is the size of WindMIL Therapeutics?

    WindMIL Therapeutics has 11 total employees.

  • What industry is WindMIL Therapeutics in?

    WindMIL Therapeutics’s primary industry is Biotechnology.

  • Is WindMIL Therapeutics a private or public company?

    WindMIL Therapeutics is a Private company.

  • What is WindMIL Therapeutics’s current revenue?

    The current revenue for WindMIL Therapeutics is .

  • How much funding has WindMIL Therapeutics raised over time?

    WindMIL Therapeutics has raised $45.8M.

  • Who are WindMIL Therapeutics’s investors?

    Catalio Capital Management, Forward Equity Partners, FoxKiser, Kintegral Asset Management, and Medivate Partners are 5 of 8 investors who have invested in WindMIL Therapeutics.

  • Who are WindMIL Therapeutics’s competitors?

    NexImmune, Senti Bio, Kite Pharma, Beacon Therapeutics, and DefiniGEN are some of the 83 competitors of WindMIL Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »